Table 3

Adverse effects during treatment

	SOF LED	SOF DACLA	P value
	N=51	N=77	P value
Headache	0	1 (1.2%)	0.072
Fatigue	2 (3.9%)	2 (2.6%)	0.413
Lower GIT symptoms	1 (1.9%)	2 (2.6%)	0.126
Upper GIT symptoms	2 (3.9%)	3 (3.8%)	0.467
Itching	1 (1.9%)	2 (2.6%)	0.126
Fever	0	0
Chest symptoms	1 (1.9%)	1 (1.2%)	0.765
Abdominal pain	2 (3.9%)	2 (2.6%)	0.413
Ascites	0	0
Hepatic encephalopathy	0	0
GIT haemorrhage	0	0
Haemoglobin drop below 100 g/L	1 (1.9%)	2 (2.6%)	0.126
Drop of white cell count below 3×10^∧9/L	0	0
Hyperuricaemia	9 (17.6%)	12 (15.6%)	0.189
Renal impairment due to hyperuricaemia	1 (2%)	1 (1.3%)	1
Total	20 (39.2%)	28 (36.2%)	0.523

Independent samples t-test for parametric quantitative data between the two groups.
χ² test (if less than 20% of cells have expected count <5) or Fisher exact test (if more than 20% of cells have expected count <5) for qualitative data between the two groups.
Significant level at p value <0.05.
DACLA, daclatsvir; GIT, gastrointestinal tract; LED, ledipasvir; SOF, sofosbuvir.